PDCD1 and melanoma: Clinical evidence from melanoma patients receiving ICIs showed loss of MHC class I protein expression on tumor cells to be a mechanism of primary resistance to anti-CTLA4, while MHC class II protein expression predicted response to anti-PD1 therapy [53].